Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ribavirin ANDAs Await Decision By FDA; Par, Roche Expect Launch In August

Executive Summary

Par expects a final decision on the approvability of generic versions of ribavirin by Aug. 1
Advertisement

Related Content

Ribavirin ANDAs Clear FDA; Schering Goes Generic Too
Ribavirin ANDAs Clear FDA; Schering Goes Generic Too
Par Generic Ribavirin Launch Expected In “Weeks”; ANDA Is “Approvable”
Par Generic Ribavirin Launch Expected In “Weeks”; ANDA Is “Approvable”
“Shared Exclusivity” Could Apply To Eight First-Time Generics, FDA Says
“Shared Exclusivity” Could Apply To Eight First-Time Generics, FDA Says
Ribavirin ANDAs Await ICN Petition; FDA Generic Rule Takes Effect
Pegasys Catching Up To PEG-Intron; Schering Admits “Complacency”
Generic Ribavirin Labels Will Carve Out Rebetol/PEG-Intron Indication
Generic Ribavirin Labels Will Carve Out Rebetol/PEG-Intron Indication
Advertisement
UsernamePublicRestriction

Register

PS042212

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel